EPFL and Microsoft Research scientists demonstrated ultrafast optical circuit switching using a chip-based soliton comb laser and a completely passive diffraction grating device. This particular architecture could enable an energy-efficient optical datacenter to meet enormous data bandwidth requirements in future.
Interleukin-12 - a messenger molecule of immune cells - was long considered to trigger the development of psoriasis. Now, researchers at the University of Zurich have shown that interleukin-12 does not actually cause the skin disease but protects against it. This also explains why common psoriasis drugs that block the messenger show insufficient treatment efficacy.
A common gene variant for the protein Aquaporin-1 lowers the amount of water channels in the cell membranes. This reduces water transport and leads to a higher risk of death in patients with kidney failure treated with peritoneal dialysis. In such cases, specific osmotic solutions should be used, as an international research team led by the University of Zurich has shown.
Doktorand/in Accounting / Controlling / Risk Management (70%) Hochschule Luzern - Wirtschaft, Rotkreuz
Dozent/in Supply Chain-, Netzwerk- und Prozessmanagement mit Leitungsaufgaben Hochschule Luzern - Wirtschaft
Professeur-e ordinaire ou associé-e, médecin-chef-fe du service de pharmacologie et toxicologie cliniques Université de Genève
Wissenschaftliche*r Mitarbeiter*in (60%) Hochschule Luzern - Soziale Arbeit
Wissenschaftliche/r Mitarbeiter/in Organizational Transformation, HRM & Leadership (80-100%) Hochschule Luzern - Wirtschaft
2 postes de chargé-e de cours Discipline d’enseignement: Cor HES-SO Genève
The future of learning: Student Project House opens
New book on sexual violence in the context of the church
Roche launches comprehensive genomic profiling kit to expand access to personalised cancer research
New center pools expertise to act on climate change
A new laboratory to strengthen virus research
Roche's VENTANA PD-L1 (SP263) Assay receives FDA approval as a companion diagnostic to identify certain non-small cell lung cancer patients eligible for Tecentriq (atezolizumab)
The Dyatlov pass mystery
The fickleness of fame
TB-PRACTECAL: Clinical Trial Yields Promising Results for Drug-Resistant Tuberculosis Treatment